ZA200203095B - Biphenyl derivatives used as NHE-3 inhibitors. - Google Patents

Biphenyl derivatives used as NHE-3 inhibitors.

Info

Publication number
ZA200203095B
ZA200203095B ZA200203095A ZA200203095A ZA200203095B ZA 200203095 B ZA200203095 B ZA 200203095B ZA 200203095 A ZA200203095 A ZA 200203095A ZA 200203095 A ZA200203095 A ZA 200203095A ZA 200203095 B ZA200203095 B ZA 200203095B
Authority
ZA
South Africa
Prior art keywords
nhe
inhibitors
derivatives used
biphenyl derivatives
biphenyl
Prior art date
Application number
ZA200203095A
Other languages
English (en)
Inventor
Dieter Dorsch
Norbert Beier
Peter Raddatz
Claudia Wilm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200203095B publication Critical patent/ZA200203095B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200203095A 1999-09-22 2002-04-18 Biphenyl derivatives used as NHE-3 inhibitors. ZA200203095B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19945302A DE19945302A1 (de) 1999-09-22 1999-09-22 Biphenylderivate als NHE-3-Inhibitoren

Publications (1)

Publication Number Publication Date
ZA200203095B true ZA200203095B (en) 2003-09-23

Family

ID=7922831

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203095A ZA200203095B (en) 1999-09-22 2002-04-18 Biphenyl derivatives used as NHE-3 inhibitors.

Country Status (16)

Country Link
EP (1) EP1214291A1 (xx)
JP (1) JP2004500338A (xx)
KR (1) KR20020033818A (xx)
CN (1) CN1555356A (xx)
AU (1) AU7649700A (xx)
BR (1) BR0014199A (xx)
CA (1) CA2387529A1 (xx)
CZ (1) CZ2002815A3 (xx)
DE (1) DE19945302A1 (xx)
HU (1) HUP0202891A3 (xx)
MX (1) MXPA02003087A (xx)
NO (1) NO20021407L (xx)
PL (1) PL355097A1 (xx)
SK (1) SK3342002A3 (xx)
WO (1) WO2001021582A1 (xx)
ZA (1) ZA200203095B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
DE10304374A1 (de) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10341240A1 (de) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
EP2170872B1 (en) 2007-06-28 2010-09-01 Sanofi-Aventis U.S. LLC Process for the preparation of the n-(2-chloro-4-methyl-3-thienyl)-1h- benzimidazol-2-amine hydrochloride and intermediates thereof
MX2011001821A (es) * 2008-09-02 2011-03-25 Sanofi Aventis Aminoindanos sustituidos y sus analogos, y el uso farmaceutico de los mismos.
MX345283B (es) 2008-12-31 2017-01-24 Ardelyx Inc Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
HUE028394T2 (en) 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidin Compound
CN103012200B (zh) * 2011-09-20 2014-12-17 北京大学 具有β-分泌酶抑制功能的化合物及其制备方法与应用
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
JP6377132B2 (ja) 2013-04-12 2018-08-22 アーデリクス，インコーポレーテッド Ｎｈｅ３結合化合物およびリン酸輸送の阻害方法
BR112017000691B1 (pt) 2014-07-25 2023-02-14 Taisho Pharmaceutical Co., Ltd Feniltetra-hidroisoquinolina substituído com heteroari-la, seu uso, medicamento, inibidores de nhe3, de absorção de sódio e de absorção de fósforo, promotor de secre-ção de água intestinal e fármaco profilático ou terapêu-tico para constipação
EP3565808A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
AU2018335130B2 (en) 2017-08-04 2023-02-16 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
EP3921327B1 (en) 2019-02-07 2023-04-05 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19819548A1 (de) * 1998-04-30 1999-11-04 Merck Patent Gmbh Biphenylderivate

Also Published As

Publication number Publication date
WO2001021582A1 (de) 2001-03-29
CZ2002815A3 (cs) 2002-08-14
AU7649700A (en) 2001-04-24
PL355097A1 (en) 2004-03-22
EP1214291A1 (de) 2002-06-19
HUP0202891A3 (en) 2003-11-28
NO20021407D0 (no) 2002-03-21
MXPA02003087A (es) 2003-08-20
DE19945302A1 (de) 2001-03-29
CN1555356A (zh) 2004-12-15
BR0014199A (pt) 2002-05-21
SK3342002A3 (en) 2002-07-02
KR20020033818A (ko) 2002-05-07
HUP0202891A2 (hu) 2003-02-28
CA2387529A1 (en) 2001-03-29
NO20021407L (no) 2002-03-21
JP2004500338A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
ZA200203095B (en) Biphenyl derivatives used as NHE-3 inhibitors.
ZA200202775B (en) Quinazoline derivatives as VEGF inhibitors.
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
MXPA03005838A (es) Inhibidores de antigenos de aparicion muy tardia-4.
HK1041407A1 (en) Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors.
HUP0202713A3 (en) Pteridinones as kinase inhibitors
ZA200109890B (en) Metalloprotease inhibitors.
HUP0202450A3 (en) N-heterocyclic derivatives as nos inhibitors
ZA200108735B (en) Renin inhibitors.
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
ZA200108016B (en) Pyrazolobenzodiazephines as CDK2 inhibitors.
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
ZA200204397B (en) Nitrile derivatives as cathepsin K inhibitors.
MXPA01013406A (es) Compuestos inhibidores de vla-4.
IL149097A0 (en) 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor
MXPA02005067A (es) Composicion inhibidora de la corrosion.
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
HK1047434A1 (en) Thienopyrimidines as phosphodiesterase inhibitors.
HK1047276A1 (zh) 作為pde4抑制劑的四氫噻喃2，3-二氮雜萘酮類衍生物
ZA200110053B (en) Factor via inhibitors.
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
HK1042695A1 (zh) 蛋白酶抑制劑
ZA200007405B (en) Angiogenesis inhibitors.
GB2389113B (en) B-secretase inhibitor
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.